Iskanje po repozitoriju

A+ | A- | | SLO | ENG

Objavljeno v DiRROS: 16.11.2021; Ogledov: 882; Prenosov: 254
Celotno besedilo (214,00 KB)

Povzetek: Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Ključne besede: non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Central Europe, Europe, Eastern Europe
Objavljeno v DiRROS: 12.10.2021; Ogledov: 957; Prenosov: 292
Povezava na datoteko

Povzetek: : Phenological events are good indicators of the effects of climate change, since phenological phases are sensitive to changes in environmental conditions. Although several national phenological networks monitor the phenology of different plant species, direct observations can only be conducted on individual trees, which cannot be easily extended over large and continuous areas. Remote sensing has often been applied to model phenology for large areas, focusing mostly on pure forests in which it is relatively easier to match vegetation indices with ground observations. In mixed forests, phenology modelling from remote sensing is often limited to land surface phenology, which consists of an overall phenology of all tree species present in a pixel. The potential of remote sensing for modelling the phenology of individual tree species in mixed forests remains underexplored. In this study, we applied the seasonal midpoint (SM) method with MODIS GPP to model the start of season (SOS) and the end of season (EOS) of six different tree species in Slovenian mixed forests. First, substitute locations were identified for each combination of observation station and plant species based on similar environmental conditions (aspect, slope, and altitude) and tree species of interest, and used to retrieve the remote sensing information used in the SM method after fitting the best of a Gaussian and two double logistic functions to each year of GPP time series. Then, the best thresholds were identified for SOS and EOS, and the results were validated using cross-validation. The results show clearly that the usual threshold of 0.5 is not best in most cases, especially for estimating the EOS. Despite the difficulty in modelling the phenology of different tree species in a mixed forest using remote sensing, it was possible to estimate SOS and EOS with moderate errors as low as <8 days (Fagus sylvatica and Tilia sp.) and <10 days (Fagus sylvatica and Populus tremula), respectively.
Ključne besede: phenology modelling, start of season, end of season, remote sensing, MODIS GPP, vegetation indices, threshold methods
Objavljeno v DiRROS: 23.08.2021; Ogledov: 949; Prenosov: 695
Celotno besedilo (2,63 MB)
Gradivo ima več datotek! Več...

Ključne besede: društva, Pro Silva Slovenija, sonaravno gospodarjenje, gozdarstvo, gozdovi
Objavljeno v DiRROS: 02.08.2021; Ogledov: 1146; Prenosov: 266
Celotno besedilo (56,69 KB)

Povzetek: Background: Hypoxia correlates with poor prognosis in several cancer types, including lung cancer. Prolyl hydroxylase domain proteins (PHDs) play a role in cell oxygen sensing, negatively regulating the hypoxia-inducible factor (HIF) pathway. Our study aim was to evaluate PHD1, PHD2 and PHD3 mRNA expression levels in primary tumours and normal lungs of non-small-cell lung cancer (NSCLC) patients and to correlate it with selected regulators of HIF signalling, with clinicopathological characteristics and overall survival (OS). Methods: Tumour tissue samples were obtained from 60 patients with surgically resected NSCLC who were treated with radical surgery. In 22 out of 60 cases, matching morphologically normal lung tissue was obtained. PHD1, PHD2 and PHD3 mRNA expressions were measured using RT-qPCR. Results: The PHD1 and PHD2 mRNA levels in primary tumours were significantly decreased compared to those in normal lungs (both p < 0.0001). PHD1 and PHD2 expression in tumours was positively correlated (rs = 0.82; p < 0.0001) and correlated well with HIF pathway downstream genes HIF1A, PKM2 and PDK1. Decreased PHD1 and PHD2 were associated with larger tumour size, higher tumour stage (PHD1 only) and squamous cell carcinoma. Patients with low PHD1 and patients with low PHD2 expression had shorter OS than patients with high PHD1 (p = 0.02) and PHD2 expression (p = 0.01). PHD1 showed borderline independent prognostic values in multivariate analysis (p = 0.06). In contrast, we found no associations between PHD3 expression and any of the observed parameters. Conclusions: Our results show that reduced expression of PHD1 and PHD2 is associated with the development and progression of NSCLC. PHD1 could be further assessed as a prognostic marker in NSCLC.
Ključne besede: non-small-cell lung carcinoma, prognosis, non-small cell lung cancer, mRNA expression, prolyl hydroxylase domain proteins
Objavljeno v DiRROS: 21.05.2021; Ogledov: 1242; Prenosov: 882
Celotno besedilo (820,49 KB)
Gradivo ima več datotek! Več...